Catalent will produce millions of extra doses of Johnson & Johnson’s COVID-19 vaccine at its recently expanded Bloomington, Ind. facility, according to a statement posted on LinkedIn.
Bloomberg broke the news yesterday, reporting that FDA has authorized the use of the facility to make the J&J vaccine.
Catalent announced late last year that it would spend $50 million to install an additional high-speed vial filling line in Bloomington. The company last year also agreed to make Moderna’s COVID-19 vaccine.
The COVID-19 vaccine manufacturing partnership between Catalent and J&J is but the latest in a string of partnerships meant to boost vaccine development and enable the U.S. to reach President Joe Biden’s goal of some post-pandemic normalcy by July Fourth. Other recent announcements include:
- Baxter’s plans to make 60–90 million doses of the Moderna vaccine in 2021, also in Bloomington;
- Merck providing two U.S. facilities to produce COVID-19 vaccine for its rival J&J.